A comparative analysis of the safety profile of direct oral anticoagulants using the FDA adverse event reporting system
- 22 April 2019
- journal article
- research article
- Published by Wiley in European Journal of Haematology
- Vol. 103 (1) , 43-46
Abstract
Introduction: Direct oral anticoagulants (DOACs) are being increasingly used. However, unlike warfarin, less is known regarding their long‐term side effects. To better evaluate the rates of DOAC‐related adverse events (AEs) on a population level, we examined AEs reported to the FDA for three commonly used DOACs and warfarin.Methods: We evaluated the FDA Adverse Event Reporting System (FAERS) database, which compiles reported drug‐related AEs from 1969 onwards. The safety profiles of the included drugs were assessed by comparing AEs per outpatient prescription and with proportional reporting ratios (PRR).Results: Rivaroxaban had the highest proportion of reported AEs. Most notably the rate for breakthrough venous thromboembolism (VTE) was higher than other DOACs. Dabigatran had the highest reported rates of ischemic stroke. When the DOAC data were analyzed using PRR, reported rates of VTE were again higher with rivaroxaban while dabigatran again showed slightly higher than expected rates of ischemic stroke. Apixaban did not show higher than expected rates in any category.Conclusion: Our analysis found rates of reported breakthrough VTE were significantly higher with rivaroxaban, while apixaban had no higher than expected rates of any studied AEs.Keywords
This publication has 12 references indexed in Scilit:
- Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin, Stratified by Stroke Risk in Patients With Atrial FibrillationThe American Journal of Cardiology, 2018
- Signals of bleeding among direct-acting oral anticoagulant users compared to those among warfarin users: analyses of the post-marketing FDA Adverse Event Reporting System (FAERS) database, 2010–2015Therapeutics and Clinical Risk Management, 2018
- Direct Oral Anticoagulants and the Paradigm Shift in the Management of Venous ThromboembolismSeminars in Thrombosis and Hemostasis, 2018
- COMPARISON OF EFFECTIVENESS, SAFETY, AND THE NET CLINICAL OUTCOME BETWEEN DIFFERENT DIRECT ORAL ANTICOAGULANTS IN 162,707 NON-VALVULAR ATRIAL FIBRILLATION PATIENTS TREATED IN US CLINICAL PRACTICEJACC, 2018
- Betrixaban (Bevyxxa): A Direct-Acting Oral Anticoagulant Factor Xa Inhibitor.2018
- Mortality and oral anticoagulants in the Food and Drug Administration Adverse Event Reporting SystemOpen Heart, 2017
- Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial FibrillationJournal of the American Heart Association, 2016
- Dabigatran Etexilate and Risk of Myocardial Infarction, Other Cardiovascular Events, Major Bleeding, and All‐Cause Mortality: A Systematic Review and Meta‐analysis of Randomized Controlled TrialsJournal of the American Heart Association, 2014
- Biases affecting the proportional reporting ratio (PRR) in spontaneous reports pharmacovigilance databases: the example of sertindolePharmacoepidemiology and Drug Safety, 2003
- Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reportsPharmacoepidemiology and Drug Safety, 2001